Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMNESTROGEN vs ACLOVATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and promoting development and maintenance of female reproductive tissues and secondary sex characteristics.
Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
Treatment of moderate to severe vasomotor symptoms due to menopause,Treatment of vulvar and vaginal atrophy due to menopause,Prevention of postmenopausal osteoporosis,Estrogen replacement therapy in female hypogonadism,Palliative treatment of advanced breast cancer in selected postmenopausal women,Palliative treatment of advanced prostate cancer
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., atopic dermatitis, contact dermatitis, eczema, psoriasis) - FDA approved,Off-label: Treatment of mild to moderate plaque psoriasis, seborrheic dermatitis, and lichen planus
1 tablet (2.5 mg estradiol and 0.625 mg norgestimate) orally once daily
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
Terminal elimination half-life is 13-18 hours; steady-state achieved after 5-7 days.
Terminal elimination half-life: approximately 6-8 hours after topical application; systemic absorption is minimal under normal use.
Hepatic metabolism via cytochrome P450 enzymes (CYP3A4 and others); undergoes enterohepatic recirculation.
Aclovate is metabolized in the skin and liver via ester hydrolysis to inactive metabolites. Systemic metabolism primarily involves cytochrome P450 enzymes (CYP3A4) for any absorbed fraction, but extensive first-pass metabolism limits systemic exposure.
Primarily renal (90-95%) as glucuronide and sulfate conjugates; biliary/fecal elimination accounts for <5%.
Renal (primarily as metabolites, <5% unchanged), biliary/fecal (minor).
98% bound primarily to albumin and sex hormone-binding globulin (SHBG).
Approximately 90%, primarily to albumin and corticosteroid-binding globulin (CBG).
1.0-1.5 L/kg; indicates extensive tissue distribution and binding.
Not well-characterized in topical use; after systemic absorption, Vd is approximately 1-2 L/kg, indicating distribution into tissues.
Oral: 2-10% due to first-pass metabolism; IM: 100%; Transdermal: 5-15%; Vaginal: 5-25%.
Topical: approximately 1-3% systemic absorption on intact skin; increased up to 15% on occluded or damaged skin.
No specific dose adjustment required; use with caution in severe impairment (e GFR <30 m L/min/1.73m²) due to potential fluid retention
No dose adjustment required. Topical use with minimal systemic absorption.
Contraindicated in Child-Pugh class B and C; for class A, use lowest effective dose with monitoring
No dose adjustment required. Topical use with minimal systemic absorption.
Not indicated for pediatric use; safety and efficacy not established
Use smallest amount effective for shortest duration. Avoid prolonged use, occlusive dressings, or application to large surface areas. Safety in children <1 year not established.
Use lowest effective dose for shortest duration; increased risk of stroke, dementia, and breast cancer; consider alternative therapies
Use with caution due to increased risk of skin atrophy and systemic absorption. Limit frequency and duration; avoid occlusive dressings.
Estrogens increase the risk of endometrial cancer in postmenopausal women with an intact uterus. Estrogen-progestin therapy increases the risk of cardiovascular events, breast cancer, and probable dementia. Estrogen-alone therapy increases the risk of stroke and deep vein thrombosis.
No FDA black box warning.
Cardiovascular disorders (stroke, MI, thromboembolism), malignant neoplasms (endometrial cancer, breast cancer), probable dementia (use >65 years), gallbladder disease, hypercalcemia, visual abnormalities, elevated blood pressure, hereditary angioedema, hypertriglyceridemia, fluid retention, hypothyroidism, exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, SLE, hepatic hemangiomas, and conditions aggravated by fluid retention.
Topical corticosteroids can cause hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with prolonged use, large surface area, occlusion, or in pediatric patients.,Reversible HPA axis suppression may occur after discontinuation.,Systemic effects including Cushing's syndrome, hyperglycemia, and glucosuria have been reported.,Local adverse reactions: burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria.,Use caution in patients with impaired skin integrity or areas of skin atrophy.,Pediatric patients may be more susceptible to systemic toxicity due to higher skin surface-to-body-weight ratio.
Known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected breast cancer (except selected patients), known or suspected estrogen-dependent neoplasia, active DVT/PE or history of thromboembolic disorders, known protein C, protein S, or antithrombin deficiency, known thrombophilic disorders, active or recent arterial thromboembolic disease (e.g., stroke, MI), known liver impairment or disease, known hypersensitivity to any ingredient.
Hypersensitivity to alclometasone dipropionate or any component of the formulation.,Untreated bacterial, fungal, or viral skin infections (e.g., herpes simplex, varicella, tuberculosis of the skin).
Grapefruit and grapefruit juice may increase estrogen levels; avoid large amounts. No significant food interactions reported but take with or without food consistently to maintain stable absorption.
No known food interactions with topical Aclovate.
First trimester: Increased risk of congenital anomalies including cardiovascular defects and neural tube defects. Second and third trimesters: Risk of urogenital tract abnormalities, feminization of male fetus, and potential long-term reproductive effects. Use contraindicated in pregnancy.
Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be ruled out. Avoid extensive use or prolonged treatment, especially in first trimester. Second and third trimester: Use only if clearly needed, minimal area and duration.
Contraindicated during breastfeeding. Amnestrogen is excreted in breast milk; M/P ratio unknown. Potential for serious adverse effects in nursing infants including hormonal disruption.
Safety unknown; likely minimal systemic absorption due to low potency. M/P ratio not established. Avoid application to breasts or large areas; use caution.
Not applicable as drug is contraindicated in pregnancy. No dose adjustment recommended due to avoidance of use.
No standard dose adjustment required; however, limit potency, frequency, and duration to lowest effective due to altered skin permeability. No pharmacokinetic changes necessitate dose change.
Amnestrogen (estrogen-progestin combination) is used for hormone replacement therapy. Monitor for thromboembolic events; avoid in patients with history of DVT/PE. Use lowest effective dose for shortest duration. Not for use in pregnancy; contraindicated in breast cancer. May increase risk of endometrial cancer if used without progestin in women with intact uterus.
Topical corticosteroids like Aclovate are classified as low-potency (Group VI). They are suitable for thin skin areas (e.g., face, flexures) and for children. Avoid prolonged use without interruption to minimize systemic absorption, especially in pediatric patients due to higher skin surface area-to-body weight ratio.
Take exactly as prescribed; do not skip doses.,Report immediately any signs of blood clots: sudden leg pain, chest pain, shortness of breath, or vision changes.,Avoid smoking while on this medication; increases clot risk.,Do not use during pregnancy; if pregnancy occurs, stop and contact doctor.,Regular breast exams and mammograms are recommended.,May cause nausea; take with food or at bedtime.
Apply a thin layer to affected skin only, not to normal surrounding skin.,Do not cover with bandages or dressings unless directed by your doctor.,Use for the prescribed duration; do not use longer than 2 weeks at a time.,Avoid contact with eyes, mouth, and open wounds.,Report any signs of skin thinning, redness, or irritation to your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMNESTROGEN vs ACLOVATE, answered by our medical review team.
AMNESTROGEN is a Estrogen that works by Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and promoting development and maintenance of female reproductive tissues and secondary sex characteristics.. ACLOVATE is a Topical Corticosteroid that works by Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMNESTROGEN and ACLOVATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMNESTROGEN is: 1 tablet (2.5 mg estradiol and 0.625 mg norgestimate) orally once daily. The standard adult dose of ACLOVATE is: Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMNESTROGEN and ACLOVATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMNESTROGEN is classified as Category C. First trimester: Increased risk of congenital anomalies including cardiovascular defects and neural tube defects. Second and third trimesters: Risk of urogenital tract abnormalitie. ACLOVATE is classified as Category C. Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.